Delisting riskPopularity #4,263
RNTX · NASDAQ · Biotechnology

Rein Therapeutics (RNTX)

Develops peptide candidates for pulmonary fibrosis and related lung diseases.

$0.7704
vs last close−0.02 (−3.06%)

Something off on this page? Send us feedback.

Next report
Nov 13, 26
in 51 days
EPS estimate
−$0.10
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Dec '24Apr '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.89−$0.26−$0.28−$0.21−$1.09−$0.19−$0.10Pending
Estimate−$0.46−$0.14−$0.22−$0.24−$1.09−$0.49−$0.17−$0.10
Surprise−310.7%−85.7%−27.3%+12.5%0.0%+61.2%+41.2%

RevenueReportedEstimate

Dec '24Apr '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.12
Sep 2027−$0.11
Jun 2027−$0.10
Mar 2027−$0.10
Dec 2026−$0.13
Nov 2026−$0.10
Aug 2026−$0.17−$0.10+41.2%
May 2026−$0.49−$0.19+61.2%
Mar 2026−$1.09−$1.090.0%
Nov 2025−$0.24−$0.21+12.5%
Aug 2025
Apr 2025
Dec 2024
Nov 2024
Aug 2024
May 2024
Dec 2023
Sep 2023
Aug 2023
May 2023−$0.60
Mar 2023−$1.30

The latest year is open to everyone — the 11 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.12$0
Sep 2027−$0.11$0
Jun 2027−$0.10$0
Mar 2027−$0.10$0
Dec 2026−$0.13$0
Nov 13, 2026−$0.10$0
Aug 14, 2026−$0.17−$0.10+41.2%+2.4%
May 15, 2026−$0.49−$0.19+61.2%−7.1%
Mar 26, 2026−$1.09−$1.090.0%−1.6%
Nov 14, 2025−$0.24−$0.21+12.5%−7.4%
Aug 14, 2025
Apr 7, 2025
Dec 31, 2024
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Dec 31, 2023
Sep 30, 2023
Aug 11, 2023
May 8, 2023−$0.60
Mar 20, 2023−$1.30

The latest year is open to everyone — the 11 quarters behind it read with an account.